10:04 AM EST - Acerus Pharmaceuticals Corporation : Announced that it has entered into a three-year agreement with Amneal Pharmaceuticals Inc. to co-promote NATESTO in the U.S. Endocrinology segment, leveraging the company’s extensive relationships with Endocrinology healthcare providers. Amneal will promote NATESTO through its 50+ sales representatives in a P2 position. Acerus Pharmaceuticals Corporation
shares T.ASP are trading unchanged at $0.05.
